<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02490969</url>
  </required_header>
  <id_info>
    <org_study_id>BIC 19</org_study_id>
    <nct_id>NCT02490969</nct_id>
  </id_info>
  <brief_title>Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19</brief_title>
  <acronym>proCORE</acronym>
  <official_title>Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Registry of an interventional Study-proved Strategy (BIC-8) using Copeptin and Troponin for&#xD;
      the Early Rule-Out of Acute Myocardial Infarction (AMI) in Patients with Suspected Acute&#xD;
      Coronary Syndrome (ACS) and a low-to intermediate risk profile.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Registry of an interventional Study-proved Strategy (BIC-8) using Copeptin and Troponin for&#xD;
      the Early Rule-Out of Acute Myocardial Infarction (AMI) in Patients with Suspected Acute&#xD;
      Coronary Syndrome (ACS) and a low-to intermediate risk profile.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To monitor the safety of the early rule-out strategy using combined testing of copeptin and&#xD;
      troponin at admission of patients with signs and symptoms suggestive of ACS and a low- to&#xD;
      intermediate risk profile, who are discharged or moved to another hospital after testing&#xD;
      copeptin and troponin negative (defined as copeptin below 10 pmol/l and cardiac troponin&#xD;
      below 99th percentile URL).&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To monitor routine application of the early rule-out strategy, patient characteristics,&#xD;
           risk profile of all patients tested for copeptin and troponin at admission, irrespective&#xD;
           of their biomarker test result&#xD;
&#xD;
        -  To monitor diagnoses, clinical course and outcome of all patients tested for copeptin&#xD;
           and troponin at admission&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">May 23, 2017</completion_date>
  <primary_completion_date type="Actual">May 23, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>28 Days</target_duration>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days</time_frame>
    <description>One-month all-cause mortality in patients in whom acute myocardial infarction is ruled-out using the early rule-out strategy and who are therefore discharged from the ED</description>
  </primary_outcome>
  <enrollment type="Actual">2256</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Routine management observation</intervention_name>
    <description>Early rule out of myocardial infarction with combined copetine and troponin testing at admission</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult men and women who present to an ED/CPU with signs and symptoms suggestive of acute&#xD;
        coronary syndrome (NSTE-ACS) and an intermediate-to low risk profile in whom an early&#xD;
        rule-out strategy for AMI is applied and who therefore undergo single combined troponin and&#xD;
        copeptin testing at admission as part of standard management.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admission to the Emergency Department or CPU with signs and symptoms consistent with&#xD;
             acute coronary syndrome&#xD;
&#xD;
          -  Low-to intermediate risk profile (GRACE-score below 140 and a low- to intermediate&#xD;
             likelihood of ACS as judged by the treating physician)&#xD;
&#xD;
          -  Patients eligible for the early rule-out strategy using combined copeptin and troponin&#xD;
             testing at admission, irrespective of biomarker test results and disposition decision&#xD;
&#xD;
          -  full-aged patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Moeckel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>June 25, 2015</study_first_submitted>
  <study_first_submitted_qc>July 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2015</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Martin Moeckel</investigator_full_name>
    <investigator_title>Univ. Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>copeptin</keyword>
  <keyword>rule out marker, emergency department, cheast pain unit</keyword>
  <keyword>emergency department</keyword>
  <keyword>chest pain unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Insipidus</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will be shared on reasonable request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

